OM
NKTR icon

Opaleye Management’s Nektar Therapeutics NKTR Stock Holding History

Opaleye Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-5,333
Closed -$4.78M – 41
2017
Q4 		$4.78M Buy
+5,333
New +$3.15M 1.53% 20
2016
Q2 		– Sell
-3,333
Closed -$688K – 53
2016
Q1 		$688K Buy
+3,333
New +$640K 0.43% 44

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Opaleye Management's NKTR Position: Q1 2018 in Review

Opaleye Management sold out of Nektar Therapeutics (NKTR) in Q1 2018, closing a stake of 5,333 shares — an estimated $4.78M sold.

Opaleye Management first reported a position in NKTR in Q1 2016 and held it in 2 quarters. The position peaked at $4.78M in Q4 2017. 359 funds tracked by Wall St. Rank hold NKTR as of Q1 2018.

  • Opaleye Management reported no remaining Nektar Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Opaleye Management sold 5,333 Nektar Therapeutics shares in Q1 2018, an estimated $4.78M.
  • Opaleye Management first reported a position in Nektar Therapeutics in Q1 2016 and held it in 2 quarters.
  • Opaleye Management's Nektar Therapeutics position peaked at $4.78M in Q4 2017.
  • 359 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2018.

Based on Opaleye Management's 13F filing for Q1 2018, filed 14 May 2018.